Honghua Jiang

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

Bernhard Ludvik, Juan P. Frías, Francisco J. Tinahones et al. · The Lancet Diabetes & Endocrinology · 2018 · 261 citations · Full text

Medicine, Endocrinology, Pharmacology +16

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

Lawrence Blonde, Johan Jendle, Jorge Luiz Gross et al. · The Lancet · 2015 · 225 citations

Medicine, Endocrinology, Pharmacotherapy +11

Racial and Ethnic Differences in Mean Plasma Glucose, Hemoglobin A1c, and 1,5-Anhydroglucitol in Over 2000 Patients with Type 2 Diabetes

William H. Herman, Kathleen Dungan, Bruce H. R. Wolffenbuttel et al. · The Journal of Clinical Endocrinology & Metabolism · 2009 · 213 citations

Medicine, Endocrinology, Internal Medicine +13

Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents

Julio Rosenstock, Andrew Ahmann, Gildred Colon et al. · Diabetes Care · 2007 · 192 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus

Keith C. Ferdinand, William B. White, David A. Calhoun et al. · Hypertension · 2014 · 143 citations

Medicine, Pharmacology, Pharmacotherapy +17